Literature DB >> 9269314

Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate.

A C Miller1, T Whittaker, A Thibault, D Samid.   

Abstract

The aromatic fatty acids phenylacetate (PA) and phenylbutyrate (PB) are novel antitumour agents currently under clinical evaluation. Their ability to induce tumour differentiation in laboratory models and their low clinical toxicity profile makes them promising candidates for combination with conventional therapies. In the present studies, we characterized the interactions between these aromatic fatty acids and radiation, using as a model cell lines derived from cancers of the prostate, breast, brain and colon. Analysis of the radiation response of the tumour lines using the linear-quadratic model, demonstrated that cellular exposure to pharmacological, non-toxic concentrations of either PA or PB resulted in time-dependent and contrasting changes in radiation response. While drug pretreatment for 24 h reduced radiation sensitivity (significant alterations in both alpha and beta parameters), pre treatment for 72 h significantly increased radiosensitivity (significant alterations in alpha and beta parameters). In replicating tumour cells, these changes were accompanied by a gradual G1-phase arrest. Cytostasis alone, however, could not explain radiosensitization, as similar alterations in radiation response were documented also in non-cycling cells. Modulation of tumour radiobiology by PA and PB was tightly correlated with early rise followed by decline in intracellular glutathione levels and the activity of antioxidant enzymes such as catalase, superoxide dismutase, glutathione reductase, glutathione peroxidase and glutathione S-transferase. Although in vitro findings identify the aromatic fatty acids PA and PB as a new class of non-toxic modulators of radiation response, the antagonistic effect of these compounds on radiation response needs further examination. Our data strongly suggest that for PA or PB to have a role in clinical radiotherapy, appropriate scheduling of combination therapies must take into account their time-dependent effects in order to achieve clinical radiosensitization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9269314     DOI: 10.1080/095530097143437

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  5 in total

1.  Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells.

Authors:  M Goh; F Chen; M T Paulsen; A M Yeager; E S Dyer; M Ljungman
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

2.  Radioprotection by the histone deacetylase inhibitor phenylbutyrate.

Authors:  Alexandra C Miller; Stuart Cohen; Michael Stewart; Rafael Rivas; Paul Lison
Journal:  Radiat Environ Biophys       Date:  2011-09-03       Impact factor: 1.925

Review 3.  Killing tumours by ceramide-induced apoptosis: a critique of available drugs.

Authors:  Norman S Radin
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

4.  Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.

Authors:  George R Blumenschein; Merrill S Kies; Vassiliki A Papadimitrakopoulou; Charles Lu; Ashok J Kumar; Justin L Ricker; Judy H Chiao; Cong Chen; Stanley R Frankel
Journal:  Invest New Drugs       Date:  2007-10-25       Impact factor: 3.850

5.  1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells.

Authors:  N Dunlap; G G Schwartz; D Eads; S D Cramer; A B Sherk; V John; C Koumenis
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.